Congestive Heart Failure · 2011 · 15 citations · 14 references
MedicineCardiologyInternal MedicineCardiac TransplantationNeuromuscular DisordersTransplant SurgeryHeart FailureHeart TransplantationMitochondrial CardiomyopathyMitochondrial DisordersCardiac Conduction AbnormalitiesCardiac PacemakersCardiac Transplantation CareChronic Progressive External OphthalmoplegiaCoenzyme Q10 DeficiencyImplantable Cardioverter DefibrillatorsKearns-sayre SyndromePigmentary Retinopathy
A 24-year-old man with Kearns–Sayre Syndrome (KSS), multiple transient ischemic attacks, dilated cardiomyopathy (ejection fraction, 15%), and diastolic dysfunction was admitted with decompensated heart failure. The patient (Figure 1) also had had progressive muscle weakness, progressive external ophthalmoplegia (PEO), pigmentary retinopathy, and ptosis since 5 years of age. He had a normal intelligence quotient. At 11 years old he was diagnosed with KSS by skeletal muscle biopsy and was placed on a mitochondrial vitamin cocktail including coenzyme Q10. A pacemaker was initially implanted when he was 8 years old after developing complete heart block and had subsequently been upgraded twice. Two months prior to admission, the patient had initially presented to our institution for a generator change for his biventricular pacemaker and was upgraded to a biventricular pacemaker (St Jude Medical, St Paul, MN) and an automatic implantable cardioverter-defibrillator. Patient with visible ptosis. During admission, the patient rapidly worsened and required an intra-aortic balloon pump for hemodynamic support and subsequently received a heart transplant 10 days later. His postoperative course was relatively unremarkable. He was discharged home 25 days after transplant on an immunosuppressive regimen of prednisone, mycophenolate mofetil, and tacrolimus. It has now been more than 1 year since his transplant and his cardiac and neurologic status remain stable. A sample of the patient’s native cardiac muscle was prepared for histopathologic and biochemical studies. Histochemical sections (Figure 2), electron microscopy (Figure 3), and immunofluorescent studies showed some of the cardinal findings of mitochondrial DNA (mtDNA) disease including ragged-red fibers. His respiratory chain enzyme analysis showed decreased activities of respiratory chain complexes containing mtDNA-encoded subunits. The mtDNA testing revealed a large heteroplasmic deletion. Histochemical sections through the patient’s cardiac muscle. (A) Cardiac myofibers with internalized nuclei, nuclear atypia, and fiber hypertrophy (hematoxylin and eosin stain). (B) Increased mitochondria with a “ragged” red pattern (Gomori trichrome). (C) Increased oxidative activity consistent with mitochondrial proliferation (NADH-tetrazolium reductase). (D) Isolated pale (arrow head) and partially pale myofibers (arrows) with variable degrees of deficiency for cytochrome c oxidase are seen. (A) Florid mitochondrial proliferation. (B) Abnormal tubular (arrow) and concentric (arrow head) mitochondrial cristae. KSS is a multisystemic disorder defined by the triad of onset before age 20, pigmentary retinopathy, and PEO.1, 2 Our patient had the classic triad plus a cardiac conduction defect. Both his skeletal and cardiac muscle biopsies showed the classic histopathologic findings seen in mitochondrial diseases including a large heteroplasmic deletion on mtDNA testing. Heteroplasmy refers to the unequal distribution of mutated mitochondria throughout the body that affects some organs more than others. Most often, the same tissue can have normal and deficient mitochondria (Figure 4). It is the ratio of normal to abnormal mitochondria that determines the degree of impairment in each particular tissue or organ. In our patient, the most impaired organs included his heart, eyes, and skeletal muscle. Immunofluorescence for complex IV-I (A) and complex IV-IV (B) of the electron transport chain on frozen tissue sections showing isolated fibers with total (arrows) or partial (arrow head) deficiency for these proteins. Partially deficient fibers are consistent with heteroplasmy. The cardiac manifestations of KSS are the most important aspect of the disease for determining prognosis.3 Typically, patients develop cardiac conduction defects that progress to complete heart block and then manifest clinically as congestive heart failure, syncope, and/or sudden death. In all patients with mtDNA mutations (not just KSS patients), mortality among those with no cardiac disease is 26% vs 71% in patients with cardiomyopathy.4 More case reports exist for complete heart block as the etiology of death in KSS patients than any other arrhythmia, but some speculate that ventricular arrhythmias are the actual fatal cause of death since QT prolongation progressing to torsades de pointes has been reported.5 Currently, permanent pacemakers are indicated for all patients with neuromuscular diseases (including KSS) who have developed atrioventricular (AV) block, but prophylactic pacemaker placement prior to developing third-degree or advanced second-degree AV block is not supported by the most recent American College of Cardiology/American Heart Association/North American Society for Pacing and Electrophysiology guidelines.6 Additionally, there is currently no indication for automatic ICD placement for primary prevention in KSS patients, but many end up with an automatic ICD because they qualify based on the degree of their cardiomyopathy. Although rare, heart transplantation has previously been used to treat other mitochondrial encephalomyopathies. According to the International Society of Heart and Lung Transplantation database, 6 patients who received heart transplantation between 1990 and 2003 had a diagnosis of mitochondrial myopathy.7 The literature contains only one case report of successful cardiac transplantation for treatment of KSS8 and one case report of successful cardiac transplant in a patient with incomplete KSS.9 Additionally, the literature contains a report of two successful transplants performed in patients with a different, but similar, mitochondrial myopathy syndrome characterized by mitochondrial encephalopathy, lactic acidosis, and stroke-like symptoms.9 We managed immunosuppression in our patient no differently than our standard regimen. Interestingly, some literature demonstrates a potential beneficial side effect of immunosuppression in a patient with a mitochondrial encephalomyopathy: Research has shown that cells that contain mtDNA mutations are sensitive to oxidative stress and calcineurin inhibitors may convey a protective effect from oxidative damage in brain cells.10, 11 In fact, mice with mtDNA deletions leading to dilated cardiomyopathy that are treated with cyclosporin A have had their disease progression arrested.12 This has not been demonstrated in humans but does raise an interesting consideration in this particular patient population. Abnormal cellular energy metabolism caused by mitochondrial dysfunction in KSS is potentially fatal if cardiac complications occur. Progressive cardiomyopathy is a source of major morbidity and mortality and heart transplantation is a viable therapeutic option for KSS patients. The prognosis in KSS patients is related to the severity of their cardiac disease, so transplant effectively mitigates that risk. Other mitochondrial encephalomyopathies affect the heart to varying degrees, so determination of heart transplantation as a treatment option should be limited to a case-by-case basis. According to our research, heart transplantation cannot be generalized across all of the mitochondrial encephalomyopathies, but based on our experience it is a life-saving, successful therapy for patients with KSS.
14
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
Andrew E. Epstein, John Dimarco, Kenneth A. Ellenbogen et al. · Circulation · 2008 · 1.8K citations · Full text